Roche insists Spark deal is still on, despite lacklustre take-upShareholders in Spark Therapeutics haven’t been queueing up to take advantage of Roche’s $114.50-per-share offer, forcing an extension Share XRoche insists Spark deal is still on, despite lacklustre take-uphttps://pharmaphorum.com/news/roche-insists-spark-deal-still-on-despite-lacklustre-take-up/
Will cell and gene therapies disrupt reimbursement?Cell and gene therapies could prove disruptive in terms of the life-changing benefits they could bring to people Share XWill cell and gene therapies disrupt reimbursement?https://deep-dive.pharmaphorum.com/magazine/disruptive-technologies/will-cell-and-gene-therapies-disrupt-drug-reimbursement/
Novartis snaps up ex-US partnership with Spark on gene therapyI was at Novartis headquarters in Basel yesterday for the company’s Q4 results, and my burning question was Share XNovartis snaps up ex-US partnership with Spark on gene therapyhttps://pharmaphorum.com/news/novartis-snaps-ex-us-partnership-spark-gene-therapy/
Can Spark make a profit on its groundbreaking gene therapy?Spark Therapeutics is on the cusp of gaining the first ever approval for a gene therapy from the Share XCan Spark make a profit on its groundbreaking gene therapy?https://pharmaphorum.com/news/can-spark-make-profit-groundbreaking-gene-therapy/
